Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new WWARN study has found that nearly two-thirds of the malaria-positive patients who present to health facilities are systematically excluded from “classical” anti-malarial treatment efficacy trials.

Researcher using a multi-pipette in a lab © Simone D McCourtie, World Bank

WWRN Researchers conducted a scoping literature review to evaluate how the eligibility criteria used in anti-malarial efficacy and safety trials translate into patient selection.

Among the 176 studies included in the analysis, nearly two-thirds of the malaria-positive subjects who presented at medical facilities were excluded from anti-malarial treatment trials, and the reason for almost one-third of them was not reported.

For the results of clinical trials to have external validity, the patients included in the study must be representative of the population presenting in the general clinical settings. The studies generally adhere to the current WHO methodological recommendations, which aim at assessing drug efficacy in a consistent way, in order to detect and monitor drug resistance. However, researchers suggest pragmatic trials are also necessary to supplement the information currently available and improve the external validity of the findings of malaria clinical trials.

The full story is available on the WWARN website

Read the publication 'Malaria patient spectrum representation in therapeutic clinical trials of uncomplicated malaria: a scoping review of the literature' on the Malaria Journal website